Compare Johnson Controls International PLC (JCI) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Philip Morris International Inc. — how do they compare? Johnson Controls International PLC trades at $155.13 (market cap $93.28B), while Philip Morris International Inc. trades at $200.2 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 3.4× Johnson Controls International PLC's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Philip Morris International Inc. for 85 Days on average.
| JCI | PM | |
|---|---|---|
Market Cap | $93.28B | $312.50B |
Volume | 2,786,476 | 5,517,172 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $158.76 | $200.50 |
52-Week Low | $105.55 | $144.33 |
Typical Hold Time | 65 Days | 85 Days |
Enterprise Value | $102.12B | $355.62B |
Dividend Yield | 1.04% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $155.93, down 1.78% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with an EPS of $1.42, and raised its full-year 2026 guidance. Revenue for 2025 was $23.60B, with net income surging to $3.29B, reflecting a robust profit margin of 13.94%. Analyst sentiment is positive, with a consensus price target of $172.50 and no sell ratings among 45 analysts.
The outlook for JCI is favorable, driven by strong demand in data-center and mission-critical thermal management systems, as highlighted in recent earnings. Investment opportunities include potential upside to the consensus target and consistent dividend payments. Key risks involve elevated valuation multiples, such as a P/E of 43.92, and macroeconomic sensitivity impacting industrial demand.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
